OR WAIT null SECS
July 25, 2021
Current drug shortages based on FDA data, prepared by Formulary Watch.
Keytruda gets a full approval in endometrial cancer; while Xeljanz will miss another PDUFDA date.
July 20, 2021
The company’s stock began dropping on Tuesday with analyst expectation the FDA will issue a Complete Response Letter for tenapanor, its chronic kidney disease therapy.
July 19, 2021
Vaxneuvance is approved for 15 serotypes, including those that are major causes of disease.
July 18, 2021
FDA staff raised safety concerns ahead of the advisory panel hearing.
July 15, 2021
Several large payers are waiting on results from the National Coverage Determination.
July 12, 2021
Commercial insurers are beginning to provide coverage information on Biogen’s controversial therapy.
July 02, 2021
The move follows an April 29 vote by the FDA Oncology Drugs Advisory Committee.
July 01, 2021
The therapy, a recombinant version, was developed to address supply and manufacturing issues.
